Supplemental Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Supplemental Financial Information [Line Items]
Cash paid for interest	$ 83	$ 92	$ 2,370
Cash paid for income taxes	670	0	61
ROU Asset obtained in exchange for new operating lease liabilities	27,668	79,984
ROU Asset obtained in exchange for new finance lease liabilities	0	1,729
Purchase of minority interest in Cooksonia	0	7,390	0
Purchases of equipment through capital leases	0	0	1,981
Lease financing obligation for build-to-suit lease			6,120
Purchases of property and equipment included in accounts payable and accrued expenses	2,915	12,881	1,815
Equity received in related parties	0	8,873	61,554
Convertible financial instruments received for Cell Engineering services	4,542	29,074	0
Equity securities and warrants received for Cell Engineering services	17,450	3,423	10,000
Conversion of convertible promissory notes to preferred stock	0	0	195
Non-cash consideration paid for the acquisition of Zymergen	0	231,750	0
Common stock issued for acquisitions	6,820	40,382	15,087
Acquisition date fair value of contingent consideration liability	0	19,912	8,760
Acquisition date fair value of warrant liabilities	0	0	194,453
Settlement of contingent consideration liability	8,896	0	0
Equity issuance costs in accounts payable and accrued expenses	0	578	$ 0
Accounting Standards Update 2016-02
Supplemental Financial Information [Line Items]
ROU Asset obtained in exchange for new operating lease liabilities	0	147,744
ROU Asset obtained in exchange for new finance lease liabilities	$ 0	$ 3,397